CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Interindividual variability in efavirenz pharmacokinetics is not entirely explained by the well-recognized CYP2B6 516G-->T single nucleotide polymorphism. The aim of this study was to determine whether polymorphisms in the CYP2A6 gene can be used to enhance the predictability of efavirenz concentrations in human immunodeficiency virus (HIV)-infected native African patients.

Related collections

Author and article information

Journal

PubMed ID:: 19371316

PMC ID:: 2679106

DOI:: 10.1111/j.1365-2125.2009.03368.x

Data availability:

Comments

Comment on this article

scite_

CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

Read this article at

Hogrefe: Sustainability & Psychology

Journal

Comment on this article

CYP2B6 (c.516G-->T) and CYP2A6 (9B and/or 17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.